Quantcast

Latest imidazoles Stories

2009-05-13 07:08:00

Fixed-dose combination offers a convenient option that may help patients reduce steps to reach their blood pressure goals while decreasing patient pill burden(1) PARSIPPANY, N.J., May 13 /PRNewswire/ -- Daiichi Sankyo, Inc. today announced that the United States Food and Drug Administration (FDA) has approved the combination treatment AZOR(R) (amlodipine and olmesartan medoxomil) as initial or 'first-line' therapy in patients likely to need multiple antihypertensive agents to achieve their...

2009-05-08 07:00:00

AZTEC Trial First to Examine AZOR Using 24-Hour Ambulatory BP Measures PARSIPPANY, N.J., May 8 /PRNewswire/ -- Daiichi Sankyo, Inc. announced today that data presented at the American Society of Hypertension, Inc. (ASH) Twenty-Fourth Annual Scientific Meeting and Exposition (ASH 2009) in San Francisco from the AZOR(R) Trial Evaluating Blood Pressure Reductions and Control (AZTEC) demonstrated that a stepwise amlodipine and olmesartan medoxomil-based titration regimen provided mean 24-hour...

2009-03-24 13:12:20

Defended thesis at University of Gothenburg March 20, 2009 Clotrimazole is a common ingredient in over-the-counter skin creams. Recent results from the University of Gothenburg, Sweden, now show that it is associated with major environmental risks. "The pharmaceuticals and chemicals in everyday use form a mixture in the ocean that has a direct impact on the growth and reproduction of organisms", says scientist Tobias Porsbring. When European authorities assess environmental risks, they often...

2009-02-03 08:43:25

Nearly every patient who receives care in the intensive care unit (ICU) requires sedation. But, as researchers have discovered, not all sedation medications are equal.Researchers at the University of Vermont found use of the sedative dexmedetomidine for critically ill patients resulted in less time on a ventilator and less delirium compared to patients who were given the more commonly used drug midazolam.During the study, researchers randomized 375 critically ill ICU patients who were...

2009-02-02 10:43:00

LAKE FOREST, Ill., Feb. 2 /PRNewswire-FirstCall/ -- The Journal of the American Medical Association (JAMA) has published study results demonstrating Hospira, Inc.'s (NYSE: HSP) alpha-2 agonist Precedex (dexmedetomidine hydrochloride) for intravenous sedation provides comparable effectiveness to commonly used gamma-aminobutyric acid (GABA)-agonist midazolam for greater-than-24-hour sedation of mechanically ventilated patients in the intensive care unit (ICU). According to the journal...

2008-12-11 14:18:00

Adding Zometa to chemotherapy prior to surgery led to an additional 33% reduction in tumor size, resulting in fewer mastectomies New data are first to demonstrate direct effect of Zometa to help shrink primary tumors; further evidence of Zometa as a potential anticancer therapy EAST HANOVER, N.J., Dec. 11 /PRNewswire/ -- New data released today demonstrate that the addition of Zometa(R) (zoledronic acid) injection to standard chemotherapy before breast cancer surgery reduces the size of...

2008-10-30 12:00:21

LAKE FOREST, Ill., Oct. 30 /PRNewswire-FirstCall/ -- Hospira, Inc. , a global specialty pharmaceutical and medication delivery company, announced today that the U.S. Food and Drug Administration (FDA) approved a new indication for Precedex(R), the company's innovative drug for in-hospital sedation. This approval allows for use of Precedex in non-intubated patients requiring sedation prior to and/or during surgical and other procedures. The additional indication complements Precedex's initial...

2008-10-13 21:00:28

Olmesartan, a drug commonly used to treat high blood pressure, may play a role in reducing coronary plaque, researchers in Japan said. The trial was performed on 247 angina patients with native coronary artery lesions randomly assigned to receive 20 mg to 40mg/day of olmesartan or a placebo, and treated with a combination of beta-blockers, calcium channel blockers, diuretics, nitrates, glycemic control agents and/or statins per physician's guidance. Examinations were performed to assess...

2008-10-06 09:00:57

Genta Incorporated (OTCBB: GNTA) announced the presentation of a progress update from the Company's ongoing Phase 3 trial of Genasense(R) (oblimersen sodium) Injection, Genta's lead oncology product, in patients with advanced melanoma. A pooled analysis of data from this study, which remains blinded, was compared with the Company's previous data from a similarly designed randomized trial. The comparative analysis shows that to date AGENDA has enrolled patients with similar demographics, and...

2008-07-28 09:00:31

Barrier Therapeutics, Inc. (NASDAQ: BTRX) announced today the introduction of Xolegel CorePak(TM) for the treatment of seborrheic dermatitis. Now, patients with this chronic skin condition need only one prescription to get quick itch relief and to safely manage the overall condition long term. The two products in Xolegel CorePak are new Xebcort(TM) Gel, a 1% hydrocortisone gel, and Xolegel(R) (ketoconazole, USP) Gel, 2%. Xebcort Gel provides quick symptom relief and is presented as a 0.8...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related